Journal of Shanghai Jiao Tong University (Medical Science) >

2021 , Vol. 41 >Issue 6: 809 - 814

DOI: https://doi.org/10.3969/j.issn.1674-8115.2021.06.018

Review

Research progress of RNA m6A methylation modification in regulating tumor function and its inhibitors

  • Ya-juan HAO ,
  • Ying-bin LIU
Expand
  • 1.Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai Research Center of Biliary Tract Disease, Shanghai 200092, China
    2.Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai 200092, China
    3.Department of Biliary-Pancreatic Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine; State Key Laboratory of Oncogenes and Related Genes; Shanghai Cancer Institute, Shanghai 200120, China

Online published: 2021-06-29

Supported by

Rising-Star Program of Science and Technology Committee of Shanghai Municipality(19QA1405900);National Natural Science Foundation of China(31701124);Shanghai Key Laboratory Project of Science and Technology Committee of Shanghai Municipality(17DZ2260200)

Fold

Abstract

RNA modifications play an important role in physiology and pathology. N6-methyladenine (m6A) has been identified as a prevalent methylation modification on eukaryotic RNAs. RNA m6A can be reversible. In recent years, abnormal expression of the RNA m6A modification enzymes and binding proteins have been found in tumors, and they promote or inhibit the tumor progression by altering the mRNA m6A modification levels of the target genes. This paper reviews the important functions of FTO α-ketoglutarate dependent dioxygenase, AlkB homolog 5 (ALKBH5) and methyltransferase like 3 (METTL3) in a variety of tumors, and also reports their small molecule inhibitors.

Key words： RNA N6-methyladenine (m6A); tumor; inhibitor; FTO α-ketoglutarate dependent dioxygenase

Cite this article

Ya-juan HAO , Ying-bin LIU . Research progress of RNA m6A methylation modification in regulating tumor function and its inhibitors[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2021 , 41(6) : 809 -814 . DOI: 10.3969/j.issn.1674-8115.2021.06.018

References

1 Dominissini D, Moshitch-Moshkovitz S, Schwartz S, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq[J]. Nature, 2012, 485(7397): 201-206.
2 Meyer KD, Saletore Y, Zumbo P, et al. Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons[J]. Cell, 2012, 149(7): 1635-1646.
3 Liu JZ, Yue YN, Han DL, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation[J]. Nat Chem Biol, 2014, 10(2): 93-95.
4 Schwartz S, Mumbach MR, Jovanovic M, et al. Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5' sites[J]. Cell Rep, 2014, 8(1): 284-296.
5 Ping XL, Sun BF, Wang L, et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase[J]. Cell Res, 2014, 24(2): 177-189.
6 Zheng GQ, Dahl JA, Niu YM, et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility[J]. Mol Cell, 2013, 49(1): 18-29.
7 Jia GF, Fu Y, Zhao X, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO[J]. Nat Chem Biol, 2011, 7(12): 885-887.
8 Xiao W, Adhikari S, Dahal U, et al. Nuclear m6A reader YTHDC1 regulates mRNA splicing[J]. Mol Cell, 2016, 61(4): 507-519.
9 Roundtree IA, Luo GZ, Zhang ZJ, et al. YTHDC1 mediates nuclear export of N6-methyladenosine methylated mRNAs[J]. Elife, 2017, 6: e31311.
10 Patil DP, Chen CK, Pickering BF, et al. M6A RNA methylation promotes XIST-mediated transcriptional repression[J]. Nature, 2016, 537(7620): 369-373.
11 Chen T, Hao YJ, Zhang Y, et al. M6A RNA methylation is regulated by microRNAs and promotes reprogramming to pluripotency[J]. Cell Stem Cell, 2015, 16(3): 289-301.
12 朱正阳, 王成, 姜辰一, 等. RNA N6-甲基腺嘌呤异常修饰影响肿瘤干细胞促进恶性肿瘤发生、发展的研究进展[J]. 上海交通大学学报(医学版), 2020, 40(3): 385-390.
13 朱屿倩, 吴凌云. m6A甲基化修饰在血液系统恶性肿瘤中的作用研究进展[J]. 上海交通大学学报(医学版), 2020, 40(3): 396-401.
14 Li ZJ, Weng HY, Su R, et al. FTO plays an oncogenic role in acute myeloid leukemia as a N6-methyladenosine RNA demethylase[J]. Cancer Cell, 2017, 31(1): 127-141.
15 Cui Q, Shi HL, Ye P, et al. m6A RNA methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells[J]. Cell Rep, 2017, 18(11): 2622-2634.
16 Yang S, Wei JB, Cui YH, et al. m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade[J]. Nat Commun, 2019, 10(1): 2782.
17 Niu Y, Lin ZY, Wan A, et al. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3[J]. Mol Cancer, 2019, 18(1): 46.
18 Li J, Han Y, Zhang HM, et al. The m6A demethylase FTO promotes the growth of lung cancer cells by regulating the m6A level of USP7 mRNA[J]. Biochem Biophys Res Commun, 2019, 512(3): 479-485.
19 Liu JQ, Ren DL, Du ZH, et al. m6A demethylase FTO facilitates tumor progression in lung squamous cell carcinoma by regulating MZF1 expression[J]. Biochem Biophys Res Commun, 2018, 502(4): 456-464.
20 Huang Y, Yan JL, Li Q, et al. Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5[J]. Nucleic Acids Res, 2015, 43(1): 373-384.
21 Peng SM, Xiao W, Ju DP, et al. Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1[J]. Sci Transl Med, 2019, 11(488): eaau7116.
22 Huang Y, Su R, Sheng Y, et al. Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia[J]. Cancer Cell, 2019, 35(4): 677-691.
23 Chen BE, Ye F, Yu L, et al. Development of cell-active N6-methyladenosine RNA demethylase FTO inhibitor[J]. J Am Chem Soc, 2012, 134(43): 17963-17971.
24 Li Q, Huang Y, Liu XC, et al. Rhein inhibits AlkB repair enzymes and sensitizes cells to methylated DNA damage[J]. J Biol Chem, 2016, 291(21): 11083-11093.
25 Qiao Y, Zhou B, Zhang MZ, et al. A novel inhibitor of the obesity-related protein FTO[J]. Biochemistry, 2016, 55(10): 1516-1522.
26 Padariya M, Kalathiya U. Structure-based design and evaluation of novel N-phenyl-1H-indol-2-amine derivatives for fat mass and obesity-associated (FTO) protein inhibition[J]. Comput Biol Chem, 2016, 64: 414-425.
27 Wang RY, Han ZF, Liu BJ, et al. Identification of natural compound radicicol as a potent FTO inhibitor[J]. Mol Pharm, 2018, 15(9): 4092-4098.
28 Han XX, Wang N, Li JY, et al. Identification of nafamostat mesilate as an inhibitor of the fat mass and obesity-associated protein (FTO) demethylase activity[J]. Chem Biol Interact, 2019, 297: 80-84.
29 Wang Y, Li JY, Han XX, et al. Identification of Clausine E as an inhibitor of fat mass and obesity-associated protein (FTO) demethylase activity[J]. J Mol Recognit, 2019, 32(10): e2800.
30 Li JY, Wang Y, Han XX, et al. The role of chlorine atom on the binding between 2-phenyl-1H-benzimidazole analogues and fat mass and obesity-associated protein[J]. J Mol Recognit, 2019, 32(6): e2774.
31 Zhang SC, Zhao BS, Zhou AD, et al. m6A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program[J]. Cancer Cell, 2017, 31(4): 591-606.e6.
32 Malacrida A, Rivara M, Domizio DA, et al. 3D proteome-wide scale screening and activity evaluation of a new ALKBH5 inhibitor in U87 glioblastoma cell line[J]. Bioorg Med Chem, 2020, 28(4): 115300.
33 Barbieri I, Tzelepis K, Pandolfini L, et al. Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control[J]. Nature, 2017, 552(7683): 126-131.
34 Vu LP, Pickering BF, Cheng YM, et al. The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells[J]. Nat Med, 2017, 23(11): 1369-1376.
35 Wang Q, Chen C, Ding QQ, et al. METTL3-mediated m6A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance[J]. Gut, 2020, 69(7): 1193-1205.
36 Chen MN, Wei L, Law CT, et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2[J]. Hepatology, 2018, 67(6): 2254-2270.
37 Bedi RK, Huang D, Eberle SA, et al. Small-molecule inhibitors of METTL3, the major human epitranscriptomic writer[J]. Chem Med Chem, 2020, 15(9). DOI:10.1002/cmdc.202000011.
38 Li ML, Zhang Z, Li X, et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway[J]. Nat Genet, 2014, 46(8): 872-876.
39 Li ML, Liu FT, Zhang F, et al. Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis[J]. Gut, 2019, 68(6): 1024-1033.
40 Gao Y, Wang Z, Zhu YD, et al. NOP2/Sun RNA methyltransferase 2 promotes tumor progression via its interacting partner RPL6 in gallbladder carcinoma[J]. Cancer Sci, 2019, 110(11): 3510-3519.
Options
Outlines

/

〈 〉